Bayer submits 'son of Nexavar' cancer drug for FDA approval

Onyx CEO Tony Coles.

Bayer HealthCare Pharmaceuticals Inc.'s experimental cancer drug regorafenib -- viewed as the "son of Nexavar" from Bayer and Onyx Pharmaceuticals Inc. -- was submitted Thursday for approval to the Food and Drug Administration, the companies said. Bayer said the new drug application was submitted for regorafenib's treatment of metastatic or unresectable gastrointestinal stromal tumors in patients whose cancer continues despite prior treatments.